List of Excipients in Branded Drug FLUCONAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Unit Dose Services	FLUCONAZOLE	fluconazole	50436-5128	ALUMINUM OXIDE
Unit Dose Services	FLUCONAZOLE	fluconazole	50436-5128	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Unit Dose Services	FLUCONAZOLE	fluconazole	50436-5128	CELLULOSE, MICROCRYSTALLINE
Unit Dose Services	FLUCONAZOLE	fluconazole	50436-5128	CROSCARMELLOSE SODIUM
Unit Dose Services	FLUCONAZOLE	fluconazole	50436-5128	FD&C RED NO. 40

Generic Drugs Containing FLUCONAZOLE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	fluconazole	0054-0002	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	fluconazole	0054-0002	ORANGE
Hikma Pharmaceuticals USA Inc	fluconazole	0054-0002	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc	fluconazole	0054-0002	SODIUM BENZOATE
Hikma Pharmaceuticals USA Inc	fluconazole	0054-0002	SODIUM CITRATE

What are the Most Frequently-Used Excipients in FLUCONAZOLE?

# Of NDCs	Excipient
52	ALUMINUM OXIDE
7	ANHYDROUS CITRIC ACID
169	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
11	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
185	CELLULOSE, MICROCRYSTALLINE

Fluconazole Excipient Strategy and Commercial Opportunities

Last updated: July 31, 2026

Fluconazole is an off-patent triazole antifungal with established oral and intravenous dosage forms, high aqueous solubility, and broad generic availability. The strongest commercial opportunities are not new chemical entity protection or conventional bioavailability enhancement. They are in pediatric acceptability, sugar-free and alcohol-free liquids, ready-to-use hospital presentations, taste masking, preservative optimization, packaging, and supply reliability.

What dosage forms and strengths are available for fluconazole?

Fluconazole is marketed in tablets, oral suspension, and intravenous infusion products. The principal approved strengths are:

Dosage form	Typical strengths or concentration	Primary use
Tablets	50 mg, 100 mg, 150 mg, 200 mg	Adult and selected pediatric systemic infections
Oral suspension	10 mg/mL and 40 mg/mL after reconstitution	Pediatric and adult oral therapy
Injection	2 mg/mL	Hospital and patients unable to take oral therapy
Capsules	Marketed in some jurisdictions	Oral systemic therapy

Pfizer’s Diflucan label identifies tablets, powder for oral suspension, and injection as dosage forms. The label also states that fluconazole has high oral bioavailability, with oral exposure generally comparable to intravenous exposure at equivalent doses (Pfizer, 2022).

Fluconazole’s pharmacokinetic profile limits the commercial value of conventional formulation technologies. The drug is rapidly and extensively absorbed, and oral bioavailability is not materially affected by food. A new product therefore needs to improve administration, adherence, storage, safety, or supply economics rather than simply increase systemic exposure.

What excipients are used in fluconazole formulations?

Excipient selection depends on the dosage form, concentration, route, and target population. Public labels show several recurring excipient categories.

Fluconazole tablets

Tablet excipients commonly include diluents, binders, disintegrants, lubricants, glidants, and film-coating materials. Examples reported in product labeling include:

• Microcrystalline cellulose
• Lactose or other tablet diluents
• Pregelatinized starch
• Crospovidone or croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Titanium dioxide
• Polyethylene glycol

The exact composition varies by manufacturer. A tablet product can be developed with standard direct-compression or wet-granulation technology, subject to acceptable dissolution, content uniformity, stability, and impurity control.

The main excipient risks are not unusual for a mature immediate-release product. They include lactose intolerance concerns, colorant sensitivities, magnesium stearate variability, tablet-friability problems at low strengths, and coating defects in humid climates.

Fluconazole oral suspension

The suspension is the most attractive excipient platform for product differentiation. A typical powder-for-reconstitution system can contain:

• Sucrose or another bulk sweetener
• Suspending agents such as xanthan gum
• Wetting agents
• Colloidal silicon dioxide
• Sodium citrate and citric acid for pH control
• Sodium benzoate or another preservative
• Flavoring agents
• Colorants

Diflucan powder for oral suspension contains sucrose and other excipients that support suspension formation, palatability, and microbial control (Pfizer, 2022). The reconstituted product must maintain dose uniformity throughout the labeled in-use period, remain pourable, and redisperse with ordinary patient handling.

The commercial weaknesses of legacy suspension systems create opportunities for:

1. Sugar-free products for patients requiring reduced sugar exposure.
2. Better taste masking for children.
3. Lower-viscosity liquids that pour consistently through oral syringes.
4. Reduced sedimentation and improved redispersibility.
5. Preservative-reduced or preservative-free presentations.
6. Ready-to-use liquids that eliminate pharmacy reconstitution.
7. More compact powder bottles that reduce shipping volume.
8. Packaging with calibrated oral syringes and clear reconstitution markings.

Fluconazole injection

The intravenous product is generally a relatively simple aqueous formulation containing fluconazole, sodium chloride, and water for injection, with pH adjustment as needed. Commercial presentations can include flexible bags, glass bottles, and premixed infusion containers.

The main excipient and container priorities are:

• Physiologic tonicity
• Chemical stability
• Low particulate burden
• Compatibility with infusion sets
• Low extractables and leachables
• Protection against microbial contamination
• Reliable fill-volume control
• Cold-chain avoidance

For hospital buyers, container configuration and administration efficiency may matter more than excipient novelty. A ready-to-use bag can reduce compounding labor and medication-error risk compared with a concentrate requiring dilution.

Which excipient strategies offer the strongest commercial opportunity?

Pediatric taste masking

Pediatric oral fluconazole is the clearest formulation opportunity. Fluconazole has a bitter taste, and suspension acceptability can affect adherence in infants and children receiving repeated therapy.

Taste-masking options include:

• Ion-exchange resin complexes
• Polymer coating of drug particles
• Lipid or wax microparticles
• Cyclodextrin complexes
• Multiparticulate suspensions
• Sweetener and flavor systems
• pH adjustment within stability and tolerability limits

A successful platform must preserve rapid release after swallowing. Taste masking that delays dissolution or creates dose nonuniformity would undermine an otherwise simple generic product.

The most practical development route is often a suspension with coated or complexed particles rather than a fully novel solid dispersion. Fluconazole’s aqueous solubility means that taste-masking technology must prevent immediate contact with taste receptors without creating a prolonged-release product.

Sugar-free and low-sugar liquid formulations

Sugar-free fluconazole can target diabetic patients, institutional formularies, and caregivers seeking reduced sugar exposure. Candidate excipients include sorbitol, xylitol, maltitol, sucralose, acesulfame potassium, and high-intensity flavor systems.

The development risks include:

• Osmolality and gastrointestinal tolerance
• Dental exposure
• Polyol-related laxation at higher doses
• Preservative compatibility
• Viscosity changes
• Flavor instability
• Microbial growth in aqueous systems

A sugar-free product should not be positioned solely as a cosmetic reformulation. The commercial case is stronger when paired with a pediatric oral syringe, improved taste, simplified storage, or an extended in-use period.

Preservative-optimized products

Preservatives are useful in multidose aqueous products but can create tolerability and regulatory concerns, particularly in neonates and medically fragile children. Sodium benzoate and parabens are established options, but each requires assessment of concentration, pH dependence, exposure, and target population.

A preservative-free multidose product is technically more difficult because it requires a robust container-closure and dosing system. Unit-dose packaging, blow-fill-seal containers, or sterile single-use systems can provide a defensible commercial proposition, although packaging costs are higher.

Ready-to-use oral liquid

A ready-to-use suspension removes pharmacy labor and reconstitution errors. The product may be attractive in hospitals, specialty pharmacies, pediatric clinics, and international markets where access to purified water is inconsistent.

The principal trade-off is logistics. A ready-to-use formulation has higher shipping weight, larger storage requirements, and more demanding microbial-control requirements than a powder for reconstitution. A dual-format portfolio may therefore be more economical:

Product	Commercial advantage	Main limitation
Powder for reconstitution	Lower freight and storage cost	Reconstitution errors and caregiver burden
Ready-to-use liquid	Immediate administration	Higher shipping weight and microbial-control cost
Unit-dose liquid	Dose accuracy and hygiene	Higher packaging cost
Concentrated liquid	Smaller package	Dilution and dosing complexity

What formulation patents protect fluconazole products?

Fluconazole is an established generic active ingredient. The original composition-of-matter and primary product protection associated with Diflucan have expired. FDA-approved generic products are widely available, and routine fluconazole tablets, suspensions, and injections generally do not depend on active patent exclusivity.

Potentially relevant intellectual-property rights can still arise around:

• Taste-masked particles
• Specific suspension systems
• Sugar-free formulations
• Preservative-free multidose packaging
• Container-closure systems
• Stable concentrated solutions
• Manufacturing processes
• Fixed-dose combinations
• Novel delivery devices
• New methods of use

A formulation patent must provide more than a conventional substitution of one sweetener, flavor, binder, or preservative for another. Patent strength improves when the formulation delivers a measurable technical effect, such as improved redispersibility, reduced bitterness, longer stability, lower preservative exposure, or improved dose uniformity.

How many patents cover generic fluconazole?

No single patent count captures the relevant estate because records differ by jurisdiction, legal status, claims, and product scope. The practical conclusion is that conventional fluconazole products face limited blocking-patent risk, while narrow formulation patents may affect a specific branded or specialty presentation.

Patent review should separate:

1. Expired fluconazole compound and early formulation patents.
2. Live but narrow formulation or packaging patents.
3. Patents that have expired in the United States but remain active elsewhere.
4. Abandoned applications and patents with cancelled or amended claims.
5. Patents that cover a delivery system rather than fluconazole itself.

What is the FDA regulatory and Orange Book status of fluconazole?

Fluconazole is approved in the United States under the FDA’s abbreviated new drug application pathway for generic products. Diflucan was approved by FDA in 1990, and generic fluconazole products have been approved in multiple strengths and dosage forms (FDA, 1990; FDA, 2024).

The Orange Book is relevant for approved prescription drug products and listed patents. For an applicant developing a standard fluconazole tablet or suspension, the principal regulatory pathway is generally an ANDA supported by pharmaceutical equivalence and bioequivalence, not a new drug application based on clinical efficacy trials.

For a reformulated product, the regulatory route depends on whether the applicant can meet the requirements for a generic product or must pursue a 505(b)(2) application. A materially different dosage form, new route, new indication, or clinically meaningful formulation change can create a 505(b)(2) strategy, but it also increases development cost and regulatory exposure.

When does fluconazole lose exclusivity?

The core fluconazole exclusivity period has already ended. Generic competition is established in the United States and major international markets. There is no broad market exclusivity protecting standard fluconazole tablets, oral suspension, or injection.

Potential residual exclusivity can arise only from a specific product or use, including:

• Pediatric exclusivity attached to a qualifying FDA product
• Orphan-drug exclusivity for a distinct indication
• A later-approved formulation
• A protected method of use
• A live patent covering a particular product configuration

These rights do not restore exclusivity to the active ingredient across the fluconazole market. They can restrict only the protected product, use, or claim scope.

Which companies are challenging fluconazole patents?

The principal competitive activity is generic supply rather than high-value patent litigation. Multiple generic manufacturers have supplied fluconazole products, including large U.S. and international generic companies. The competitive field includes manufacturers such as Teva, Sandoz, Viatris, Dr. Reddy’s Laboratories, Cipla, Hikma, and other regional suppliers, depending on dosage form and market.

Paragraph IV challenges are not a central commercial barrier for ordinary fluconazole products because the foundational patent estate is expired and generic entry is mature. A Paragraph IV dispute could still arise for a newly patented formulation or method of use, but that would concern the later patent rather than standard fluconazole tablets.

What patent litigation and settlement agreements affect fluconazole?

The original Diflucan patent dispute cycle is historical. Current commercial decisions should focus on whether a proposed product reads on a live formulation, manufacturing, device, or use patent in the target jurisdiction.

A meaningful freedom-to-operate review should examine:

• U.S. Orange Book listings
• FDA patent certifications
• Patent Trial and Appeal Board proceedings
• Federal district-court litigation
• European Patent Office legal status
• National-phase patents in commercial markets
• Patent-family continuity and terminal disclaimers
• Claim scope after prosecution and litigation

Settlement agreements are unlikely to create a broad barrier for standard fluconazole generic entry. They may matter if a company licenses a taste-masking technology, specialty container, or pediatric delivery platform.

How strong is the fluconazole patent estate?

The core patent estate is weak for conventional products because the active ingredient and established dosage forms are mature. A new entrant’s defensibility must come from execution and product attributes rather than the fluconazole molecule.

Patent or protection area	Relative strength	Commercial relevance
Fluconazole composition of matter	Low or expired	Does not block ordinary generic entry
Conventional tablet formulation	Low	Limited differentiation
Standard powder suspension	Low to moderate	Usually easy to design around
Taste-masked pediatric suspension	Moderate	Potentially defensible if claims show technical effect
Sugar-free liquid	Low unless technically differentiated	Commercially useful but often design-around risk
Preservative-free packaging	Moderate	Depends on device and stability claims
Ready-to-use hospital infusion	Low to moderate	Manufacturing and supply advantages may matter more
Novel delivery device	Moderate to high	Depends on claim breadth and regulatory linkage
New indication or method of use	Variable	Can create narrow exclusivity

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more significant than active-ingredient patent barriers.

For oral suspensions, critical process controls include particle-size distribution, wetting, suspension rheology, sedimentation rate, reconstitution time, microbial limits, and content uniformity after storage. Taste-masked particles can create scale-up problems because coating thickness, agglomeration, and dissolution must remain consistent.

For injections, the main barriers include sterile processing, container-closure integrity, particulate control, extractables and leachables, and validated aseptic filling. A company with reliable sterile manufacturing can compete effectively even without strong patent protection.

For tablets, the barriers are comparatively low. Differentiation may come from low-cost manufacturing, contract-manufacturing capacity, rapid regulatory execution, and dependable supply to wholesalers and hospitals.

How does fluconazole compare with competing antifungals?

Fluconazole competes with itraconazole, voriconazole, posaconazole, isavuconazole, amphotericin B, and echinocandins. Its advantages are low cost, oral and intravenous availability, predictable absorption, and broad generic supply.

Drug	Formulation opportunity	Relative market position
Fluconazole	Pediatric liquids, ready-to-use products, hospital bags	Mature, price-competitive generic
Itraconazole	Oral solution and capsule bioavailability management	More complex absorption and interaction profile
Voriconazole	Oral and IV formulations, strong interaction management	Higher-value branded and generic segments
Posaconazole	Delayed-release tablet and suspension optimization	Higher formulation complexity
Isavuconazole	Specialty oral and IV products	Protected or recently protected markets in some jurisdictions
Amphotericin B	Lipid and conventional injectable systems	Complex injectable manufacturing
Echinocandins	Sterile injectable products	Hospital-focused, higher manufacturing barriers

Fluconazole’s low price limits the economic headroom for expensive excipient systems. The best target segments are those where formulation improvements reduce total treatment cost, administration burden, wastage, or medication errors.

What generic launch scenarios exist for a new fluconazole formulation?

A new entrant can pursue four principal launch models.

Low-cost standard generic

This model uses conventional excipients and established manufacturing. It has the lowest development risk but also the weakest differentiation and greatest price pressure.

Pediatric differentiated generic

A sugar-free, taste-masked suspension with an oral syringe can command better formulary attention. The product should demonstrate dose uniformity, acceptable palatability, stability after reconstitution, and ease of administration.

Hospital presentation

A ready-to-use 2 mg/mL infusion bag or a unit-dose presentation can compete on pharmacy efficiency and supply continuity. Hospital contracts may value reduced manipulation more than minor ingredient differences.

Specialty 505(b)(2) product

A novel route, device, or use may support a 505(b)(2) application. This route provides more commercial flexibility but requires a stronger clinical, regulatory, and intellectual-property case.

What licensing deals could support a fluconazole product?

The most valuable licensing targets are formulation and delivery technologies rather than fluconazole rights. Potential deal structures include:

• Nonexclusive taste-masking technology licenses
• Exclusive pediatric formulation rights in selected territories
• Co-development of ready-to-use hospital products
• Contract manufacturing and supply agreements
• Device licenses for unit-dose oral delivery
• Regional distribution arrangements
• Technology-transfer agreements for sterile fill-finish

A license should be assessed against fluconazole’s low unit price. Upfront payments, minimum royalties, and manufacturing restrictions can eliminate the margin available from a mature generic unless the technology supports a premium segment or institutional contract.

What is the revenue exposure for fluconazole manufacturers?

Fluconazole revenue is exposed to generic price erosion, tender competition, wholesaler substitution, and shortages caused by concentrated manufacturing capacity. Pfizer has historically disclosed Diflucan as part of broader product reporting rather than as a consistently separate current revenue category. Current commercial exposure is therefore more relevant at the product-family and supply-contract level than at the originator-brand level.

Revenue opportunities are strongest where a formulation solves a purchasing problem:

• Pediatric adherence
• Hospital labor reduction
• Reduced dosing errors
• Better stability in hot or humid markets
• Fewer stockouts
• Improved access in low-resource settings
• Lower wastage after reconstitution

Key Takeaways

• Fluconazole’s core composition-of-matter and conventional product protection have expired.
• Standard tablets face intense generic competition and limited patent-based differentiation.
• Pediatric oral suspension is the strongest excipient opportunity.
• Taste masking, sugar-free formulation, preservative reduction, and oral-syringe compatibility are commercially relevant.
• Ready-to-use hospital infusion products can compete through workflow and supply advantages.
• Fluconazole’s high oral bioavailability reduces the value of conventional solubility-enhancement technology.
• Formulation patents need a measurable technical effect to support meaningful defensibility.
• Manufacturing capability, quality consistency, and distribution reliability are more important than broad active-ingredient exclusivity.
• Licensing economics must reflect fluconazole’s low generic price.
• A new product should be positioned around administration, adherence, safety, or supply economics rather than systemic exposure.

FAQs

Is fluconazole suitable for a sugar-free pediatric suspension?

Yes. A sugar-free formulation can use polyols or high-intensity sweeteners, but developers must control osmolality, viscosity, taste, preservative performance, and gastrointestinal tolerability.

Does fluconazole require a solubility-enhancing excipient?

Usually not for conventional oral products. Fluconazole has high oral bioavailability, so excipient development should focus on taste, suspension stability, and administration rather than increasing absorption.

Can a fluconazole suspension receive new patent protection?

Yes, but protection would generally need to cover a specific formulation, particle architecture, process, packaging system, or measurable technical result. A routine sweetener substitution is vulnerable to design-around and obviousness challenges.

Is a ready-to-use fluconazole infusion commercially attractive?

It can be attractive to hospitals if it reduces pharmacy preparation, dosing errors, and waste. The business case depends on container cost, sterile manufacturing capacity, contract pricing, and supply reliability.

Are biosimilars relevant to fluconazole?

No. Fluconazole is a small-molecule drug, not a biologic. Competitive entry occurs through generic-drug pathways rather than biosimilar approval.

References

1. Food and Drug Administration. (1990). Diflucan approval history and prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Pfizer Inc. (2022). Diflucan (fluconazole) prescribing information. Pfizer Laboratories.

4. National Library of Medicine. (2024). DailyMed: Fluconazole product labeling. U.S. National Library of Medicine.

5. U.S. Pharmacopeia. (2024). Fluconazole monograph. United States Pharmacopeial Convention.